Wissenschaftliche Arbeiten

Prof. Dr. Yeşim Eralp

193 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. The predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.10539 Quelle: ORCID

  2. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

    Oncology, 2011

    DOI 10.1159/000330766 PMID 21912195 13 Zitationen (Europe PMC) Quelle: ORCID

  3. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients

    Journal of B.U.ON., 2011

    Quelle: ORCID

  4. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

    Clinical Lung Cancer, 2011

    DOI 10.1016/j.cllc.2011.03.030 PMID 21729649 6 Zitationen (Europe PMC) Quelle: ORCID

  5. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.629 5 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  6. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e13079 1 Zitation (OpenAlex) Quelle: ORCID

  7. Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients.

    Journal of Clinical Oncology, 2010

    DOI 10.1200/jco.2010.28.15_suppl.e12041 1 Zitation (OpenAlex) Quelle: OpenAlex

  8. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.

    Journal of Clinical Oncology, 2010

    DOI 10.1200/jco.2010.28.15_suppl.e19507 1 Zitation (OpenAlex) Quelle: ORCID

  9. Primary tubal cancers: a clinicopathological study of twenty cases

    Turkish Journal of Pathology, 2009

    DOI 10.5146/tjpath.2009.00978 Quelle: OpenAlex

  10. Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study.

    Cancer Research, 2009

    DOI 10.1158/0008-5472.sabcs-09-3167 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

    European Journal of Obstetrics & Gynecology and Reproductive Biology, 2009

    DOI 10.1016/j.ejogrb.2009.02.052 PMID 19419810 27 Zitationen (Europe PMC) Quelle: OpenAlex

  12. Malignant Ovarian Germ Cell Tumors

    American Journal of Clinical Oncology, 2009

    DOI 10.1097/coc.0b013e3181841f2e PMID 19307952 17 Zitationen (Europe PMC) Quelle: OpenAlex

  13. The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience

    Journal of Clinical Oncology, 2009

    DOI 10.1200/jco.2009.27.15_suppl.e22158 Quelle: ORCID

  14. BORDERLINE RESECTIONS AFTER NEO-ADJUVANT TREATMENT: SLEEVE LOBECTOMY VS. PNEUMONECTOMY

    Lung Cancer, 2009

    DOI 10.1016/s0169-5002(09)70246-6 Quelle: ORCID

  15. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Cancer Research and Clinical Oncology, 2009

    DOI 10.1007/s00432-008-0428-9 PMID 18581139 15 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  16. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer

    Tumori Journal, 2009

    DOI 10.1177/030089160909500212 PMID 19579867 6 Zitationen (Europe PMC) Quelle: ORCID

  17. Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy?

    Cancer Research, 2009

    DOI 10.1158/0008-5472.sabcs-5123 Quelle: ORCID

  18. Primary Tubal Cancers: A Clinicopathological Study of Twenty Cases

    Turk Patoloji Dergisi, 2009

    DOI 10.5146/tjpath.2009.01160 Quelle: ORCID

  19. TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER

    Journal of Breast Health, 2009

    Quelle: ORCID

  20. Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

    Cancer Investigation, 2008

    DOI 10.1080/07357900801891628 PMID 18608215 13 Zitationen (Europe PMC) Quelle: OpenAlex

  21. Ovarian Carcinoma with Simultaneous Breast and Rectum Metastases

    Onkologie, 2008

    DOI 10.1159/000119121 PMID 18418023 6 Zitationen (Europe PMC) Quelle: OpenAlex

  22. Bevacizumab – der neue Standard in der Darmkrebstherapie

    Onkologie, 2008

    DOI 10.1159/000127373 Frei zugänglicher VolltextQuelle: OpenAlex

  23. Meetings and Conferences · Tagungen und Kongresse

    Onkologie, 2008

    DOI 10.1159/000127357 Frei zugänglicher VolltextQuelle: OpenAlex

  24. PharmaNews

    Onkologie, 2008

    DOI 10.1159/000127375 Frei zugänglicher VolltextQuelle: OpenAlex

  25. Factors affecting the prognosis of breast cancer patients with brain metastases

    The Breast, 2008

    DOI 10.1016/j.breast.2008.03.004 PMID 18455400 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

    Journal of Neuro-Oncology, 2008

    DOI 10.1007/s11060-008-9769-0 PMID 19099196 14 Zitationen (Europe PMC) Quelle: OpenAlex

  27. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance

    Journal of Clinical Oncology, 2008

    DOI 10.1200/jco.2008.26.15_suppl.11563 Quelle: ORCID

  28. .ROLE OF VARIOUS METHODS OF BRACHYTHERAPY IN CARCINOMA OF VAGINA

    Radiotherapy and Oncology, 2008

    Quelle: ORCID

  29. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer

    Annals of the New York Academy of Sciences, 2008

    DOI 10.1196/annals.1448.010 PMID 18837944 22 Zitationen (Europe PMC) Quelle: ORCID

  30. Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt

    Gynecologic Oncology, 2008

    DOI 10.1016/j.ygyno.2007.09.024 PMID 17961641 20 Zitationen (Europe PMC) Quelle: ORCID

  31. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: Our long-term results,Neoadjuvan kemoterapi sonrasi meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarimiz

    Turk Onkoloji Dergisi, 2008

    Quelle: ORCID

  32. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: our long-term results

    Turk Onkoloji Dergisi, 2008

    Quelle: ORCID

  33. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

    Clinical Chemistry and Laboratory Medicine, 2008

    DOI 10.1515/cclm.2008.080 PMID 18254709 38 Zitationen (Europe PMC) Quelle: ORCID

  34. Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarımız

    Istanbul Science University (Istanbul Bilim University), 2008

    Frei zugänglicher VolltextQuelle: OpenAlex

  35. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

    Annals of Oncology, 2007

    DOI 10.1093/annonc/mdm522 PMID 18006896 51 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  36. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

    Gynecologic Oncology, 2007

    DOI 10.1016/j.ygyno.2007.09.003 PMID 17936342 37 Zitationen (Europe PMC) Quelle: OpenAlex

  37. MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer

    Breast Cancer Research and Treatment, 2007

    Quelle: ORCID

  38. Multifocal breast cancer in women

    Cancer, 2007

    DOI 10.1002/cncr.22928 PMID 17676585 24 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  39. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

    Medical Oncology, 2007

    DOI 10.1007/bf02685901 PMID 17673810 21 Zitationen (Europe PMC) Quelle: ORCID

  40. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer

    Annals of Oncology, 2006

    Quelle: ORCID

  41. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

    Annals of Oncology, 2006

    Quelle: ORCID

  42. Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer

    Journal of Clinical Oncology, 2005

    DOI 10.1200/jco.2005.23.16_suppl.2594 1 Zitation (OpenAlex) Quelle: ORCID

  43. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

    Medical Oncology, 2005

    DOI 10.1385/mo:22:4:367 PMID 16260854 1 Zitation (Europe PMC) Quelle: ORCID

  44. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients

    Acta Oncologica, 2005

    DOI 10.1080/02841860510007549 PMID 15788296 44 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  45. Thymidine Labeling index: Prognostic role in breast cancer (vol 27, pg 400, 2004)

    American Journal of Clinical Oncology, 2005

    Quelle: ORCID

  46. Thymidine Labeling Index: Prognostic Role in Breast Cancer

    American Journal of Clinical Oncology, 2004

    DOI 10.1097/01.coc.0000128867.95368.9e PMID 15289735 2 Zitationen (Europe PMC) Quelle: ORCID

  47. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.14_suppl.600 1 Zitation (OpenAlex) Quelle: ORCID

  48. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.90140.600 Quelle: ORCID

  49. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.90140.7270 Quelle: ORCID

  50. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.14_suppl.7270 Quelle: ORCID